Difference between revisions of "Finasteride (Proscar)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Endocrine therapy" to "Category:Endocrine therapeutic") |
||
| Line 18: | Line 18: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | [[Category:Endocrine | + | [[Category:Endocrine therapeutic]] |
[[Category:Antiandrogens]] | [[Category:Antiandrogens]] | ||
[[Category:5 alpha-reductase inhibitors]] | [[Category:5 alpha-reductase inhibitors]] | ||
Revision as of 17:53, 3 February 2019
General information
Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Specifically and competitively inhibits Type II 5α-reductase by forming a stable enzyme-drug complex.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Also known as
- Brand name: Proscar